profit from every $100 of sales.
$0$100
Dermata Therapeutics
We have no price for Dermata Therapeutics since 17 August 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00+0.00% today
-87.4% since Oct 10, 25
1-year low $0.001-year high $0.01
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Dermata Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$7.56 million of profit last year.
SalesProfit
Dermata Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Dermata Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Dermata Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -10 | -8 | -13 | -8 | |
| -10 | -8 | -13 | -8 | |
| -10 | -8 | -12 | -8 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7 | 8 | 4 | 8 |
| Cash | 6 | 7 | 3 | 8 |
| Total debt | – | – | – | – |
| Total liabilities | 1 | 2 | 2 | 2 |
| 6 | 6 | 2 | 6 | |
| – | – | – | – | |
| -126.9% | -100.0% | -633.2% | -98.7% | |
| -159.6% | -122.7% | -787.1% | -121.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | -6 | -11 | -8 | |
| – | – | – | – | |
| -9 | -6 | -11 | -8 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.2×
- 0.0×
- –
- 0.9×
- -62,199,799.6%
- -490.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -124.9%
- -229.5%
- -130.9%
- -96.1%
- -124.9%
- –
Growth
- –
- –
- −69,393.8%
- –
- +105.4%
Financial health
- -1.0×
- 0.00
- 0.0%
- –
- 4.79
- 4.79
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.48 | -0.53 | +9.4% |
| Mar 26, 2026 | -0.35 | -1.54 | +77.3% |
| Nov 14, 2025 | -1.65 | -1.59 | −3.7% |
| Aug 13, 2025 | -1.66 | -2.90 | +42.9% |
| May 14, 2025 | -0.45 | -4.50 | +90.1% |
| Sep 30, 2023 | -0.54 | – | – |
| Jun 30, 2023 | -1.73 | – | – |
| Dec 31, 2022 | -0.13 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
79Pass
Philip Fisher
43No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
33No pass
Terry Smith
30No pass
Questions about Dermata Therapeutics
Is Dermata Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Dermata Therapeutics AI analysis
What does Dermata Therapeutics do?
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. It is in Biotechnology.
Does Dermata Therapeutics pay a dividend?
No. Dermata Therapeutics does not pay a dividend at the moment; in 2025 it returned $367 to shareholders by buying back its own shares.
Who are Dermata Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Dermata Therapeutics's.
Prices: daily closes to Aug 17, 2026. Fundamentals: company reports via invest-like data.